February 10th 2025
New phase 3 data on CYB003 is coming. Learn more about the phase 3 pivotal program here.
New Data Shows How Best to Switch Patients With Schizophrenia to Risperidone
September 24th 2024New data informs clinicians of how best to switch patients from a once-monthly subcutaneous injection of RBP-7000 (Perseris) to risperidone (Uzedy), an extended-release injectable suspension of risperidone for subcutaneous use every 1 or 2 months for the treatment of schizophrenia in adults.
Read More
FDA Approves Erzofri for the Treatment of Schizophrenia and Schizoaffective Disorder
July 30th 2024The US Food and Drug Administration has approved Erzofri, a paliperidone palmitate extended-release injectable suspension for the treatment of adults with schizophrenia and schizoaffective disorder.
Read More